These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 24040872)

  • 1. Sodium-glucose co-transporter 2 inhibition in diabetes treatment: current evidence and future perspectives.
    Rizos EC; Elisaf MS
    Curr Pharm Des; 2014; 20(22):3647-56. PubMed ID: 24040872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
    Whalen K; Miller S; Onge ES
    Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.
    Scheen AJ
    Expert Opin Drug Saf; 2015; 14(12):1879-904. PubMed ID: 26513131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
    Kim GW; Chung SH
    Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
    Nauck MA
    Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.
    Davis CS; Fleming JW; Warrington LE
    J Am Assoc Nurse Pract; 2014 Jul; 26(7):356-63. PubMed ID: 24895099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium glucose transporter 2 (sglt2) inhibitors: Current status in clinical practice.
    Dutta D; Kalra S
    J Pak Med Assoc; 2014 Oct; 64(10):1203-6. PubMed ID: 25823168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin: a sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Dixit D; Yoon Y; Volino LR; Mansukhani RP
    Am J Health Syst Pharm; 2015 Nov; 72(22):1943-54. PubMed ID: 26541949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin: glucuretic action and beyond.
    Balakumar P; Sundram K; Dhanaraj SA
    Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS.
    Handelsman Y
    Endocr Pract; 2015 Sep; 21(9):1054-65. PubMed ID: 26132997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus.
    Mikhail N
    South Med J; 2015 Feb; 108(2):91-6. PubMed ID: 25688893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
    Chao EC
    Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
    Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibition with dapagliflozin -- a novel approach for the management of type 2 diabetes.
    Kilov G; Leow S; Thomas M
    Aust Fam Physician; 2013 Oct; 42(10):706-10. PubMed ID: 24130972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.